An observational study in Uterine Cervical Neoplasms, sponsored by Centre Paul Strauss. Recruiting at 2 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Centre Paul Strauss · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Uterine Cervical Neoplasms with a site in France — 31 open to participants now, 46 under way, 5 of them phase 3. Uterine Cervical Neoplasms · France.
Among the 147 studies in Uterine Cervical Neoplasms with a site in France, this one is the 23rd largest by planned enrollment of the 30 observational ones that give a count, is one of 9 that started in 2025, is one of 30 observational ones, reaches primary completion later than 38 of the 45 other live ones, and was the 144th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →31 of the 147 studies in Uterine Cervical Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 25–65
Merck Sharp & Dohme LLC · Sites in France, United States, Argentina and 26 more countries
Ages 18+ · Women only
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+ · Women only
Institut Claudius Regaud · Sites in France
Ages 18+
International Agency for Research on Cancer · Sites in France
Ages 30–65 · Women only · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 36 · Phase 3 14 · Phase 4 1
First in 1996; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 220 across 530 observational studies indexed under Uterine Cervical Neoplasms.
Median enrollment 210 across the 117 interventional studies, 174 across the 30 observational. Of the 92 that completed or were terminated, 15 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 147 have an industry lead sponsor. The 10 most frequent:
Centre Paul Strauss is the lead sponsor of 31 studies on the registry; 21 are open to participants now.
Centre Paul Strauss has 2 studies filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Uterine Cervical Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06392997ZIWIGEvaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology | 2026-12 |
| NCT06533059Alterome Therapeutics, Inc.A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | 2026-12-29 |
| NCT05527184AbbVieFirst in Human Study of IMGN151 in Recurrent Gynaecological Cancers | 2027-02 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT06923761Grey Wolf TherapeuticsEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) | 2027-04-30 |
Add all 12 to your calendar (.ics) → With an account.
Among the 147 studies in Uterine Cervical Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, prospective study aimed at providing information on the psychological effects (including post-traumatic stress symptoms) of utero-vaginal brachytherapy in patients with cervical cancer using self-administered questionnaires. The study also aims to assess the persistence of these symptoms over time, up to 5 years after brachytherapy. The results could help identify patients at risk of post-traumatic stress in this context and develop appropriate psychological interventions to improve their psychological well-being during and after treatment.
Patient with cervical cancer with an indication for High-dose rate (HDR) or pulse-dose rate (PDR) uterovaginal brachytherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Prospective questionnaires
Post-traumatic stress disorder Checklist version DSM-5 (PCL-5) and quality of life questionnaires
Post-Traumatic Stress Disorder evaluation
Evaluation with post-traumatic stress disorder Checklist version DSM-5 (PCL-5) - questionnaire with a Cut off score ≥ 32
Time frame: at 2 months
Anxiety and Depression
Hospital Anxiety and Depression scale
Time frame: until 60 months
Quality of Life (general module)
Evaluated with EORTC QLQ-C30 questionnaire
Time frame: until 60 months
Quality of Life (cervical cancer module)
Evaluated with EORTC QLQ-CX24 questionnaire
Time frame: until 60 months
Sexual Health evaluation
Sexual Health Questionnaire (EORTC SHQ-22)
Time frame: until 60 months
Started Nov 2025 (actual). Primary completion is estimated for Nov 2030, 60 months after the start.
Of 190 non-industry observational studies under Uterine Cervical Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 158. This study's planned 60 months is close to that.
Counting every sponsor, half of 214 studies reached it within 58 months; a quarter within 28 and three quarters within 158.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Paul Strauss